NeurAxon, headquartered in Toronto, Canada, specializes in discovering and developing next generation pain therapeutics that inhibit neuronal nitric oxide synthase, an enzyme involved in modulating pain and central nervous system neuronal sensitization. The company's pipeline includes oral products addressing various types of pain such as acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. Founded in 2004, NeurAxon is a leader in the development of selective inhibitors of nitric oxide synthase for pain management.